NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release fourth quarter and full year 2024 results after the market closes on Wednesday, January 22, 2025. The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive." The company will host a conference call on Thursday, January 23, 2025 at 10:00 a.m. (ET) with access available via webcast ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $85.8 billion as of December 31, 2024, a decrease of $5.6 billion from assets under management of $91.4 billion at November 30, 2024. The decrease was due to market depreciation of $5.7 billion and distributions of $396 million, partially offset by net inflows of $504 million.                Assets Under Management               (unaudited) ($ in millions) AUM Net Market A ...

Market Overview - The global central nervous system (CNS) therapeutics market is estimated to be USD 144.3 million in 2024 and is expected to reach USD 431.0 million by 2035, with a CAGR of 10.46% during the forecast period 2025-2035 [2] - Growth is driven by factors such as the rising prevalence of neurological disorders, improvements in drug development and approvals, increased investments in R&D, growing telemedicine and digital therapeutics adoption, and the growing use of personalized medicine [2] Disease Segmentation - The mental health therapeutics segment accounted for the highest revenue in 2024 due to the increasing prevalence of mental health disorders such as depression, anxiety, and schizophrenia, along with growing awareness and acceptance of mental health treatments [4] - The neurodegenerative diseases segment is predicted to grow at the fastest CAGR during the forecast period due to the rising incidence of conditions like Alzheimer's and Parkinson's disease, advancements in disease-modifying therapies, and a growing aging population [4] Drug Class Segmentation - The CNS stimulants segment accounted for the highest revenue in 2024 due to the growing demand for ADHD treatments and the increasing use of stimulants for managing attention-deficit hyperactivity disorder in both children and adults [5] - The anticonvulsants segment is predicted to grow at the fastest CAGR during the forecast period due to its widespread application in treating epilepsy, bipolar disorder, and neuropathic pain, along with the development of new-generation anticonvulsants with fewer side effects and improved efficacy [6] Distribution Channel Segmentation - The hospital pharmacies segment accounted for the highest revenue in 2024 due to the increasing number of hospital admissions for severe neurological and psychiatric conditions, coupled with the availability of specialized CNS treatments in hospital settings [7] - The retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period due to the expanding reach of retail pharmacy chains, rising over-the-counter availability of CNS medications, and the growing preference for outpatient treatment, particularly in emerging markets [7] Regional Analysis - North America is anticipated to have the highest revenue share during the forecast period due to the well-established healthcare infrastructure, high prevalence of neurological and mental health disorders, significant investments in R&D, and the presence of key market players [8] - The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period due to rapidly increasing healthcare spending, growing awareness of neurological and psychiatric disorders, expanding access to advanced treatments, and a large, aging population [8] Industry Trends - Biopharmaceutical companies are increasingly focusing on the development of novel therapeutics for the CNS, including disease-modifying drugs, biologics, and gene therapies [3] - For instance, in March 2024, Ultomiris received FDA approval as the first long-acting C5 complement inhibitor specifically for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) [3] - In May 2024, AC Immune and Takeda signed an exclusivity contract for the Alzheimer's immunotherapy ACI-24.060, which included an upfront payment of USD 100 million and possible milestones of USD 2.1 million [4] - In October 2024, AbbVie announced a deal to buy Aliada Therapeutics, a biotechnology company developing treatments for difficult CNS diseases using a novel blood-brain barrier (BBB)-crossing technology [5] Key Players - The report includes exhaustive company profiles of the top 10+ market players, including Pfizer Inc, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding AG, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb, Sanofi, AbbVie Inc, Merck & Co Inc, Biogen Inc, AstraZeneca PLC, GlaxoSmithKline (GSK), Amgen Inc, H Lundbeck A/S, and Teva Pharmaceutical Industries Ltd [9]

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Cohen & Steers Income Opportunities REIT, Inc. ("CNSREIT") announced today its acquisition of Bridgepointe Shopping Center, an open-air community shopping center in San Mateo, California. The acquisition was made through a programmatic joint venture with Sterling Organization ("Sterling"), a real estate investment firm with extensive expertise in shopping centers in the U.S. This is CNSREIT's third acquisition with Sterling Organization and fourth open-air shopping ce ...

NEW YORK, Dec. 18, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for January, February, and March 2025, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Pr ...

MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announces the addition of Judson Thuerk to the Channel and Alliances Team as the Channel Manager for the Americas."I am very excited to join Corero, especially at such a pivotal, high-growth moment. The company is clearly poised to become the de facto global leader in safeguarding critical infrastructure against evolving DDoS threats. Trusted p ...

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $89.7 billion as of October 31, 2024, a decrease of $2.0 billion from assets under management of $91.8 billion at September 30, 2024. The decrease was due to market depreciation of $2.3 billion and distributions of $150 million, partially offset by net inflows of $454 million. Assets Under Management(unaudited)       ($ in millions) AUM Net Market AUM By investment vehi ...

________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Indicate by check mark whether the registrant: (1) has filed all reports required to be filed ...

NEW YORK, Nov. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Karen Wilson Thissen as a director of the company. Ms. Thissen has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.Ms. Thissen is currently General Counsel and Secretary of General Mills, Inc. Prior to joining General Mills, she spent 17 years at Ameriprise Financial, Inc., serving most recently as Executive Vice ...

CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking ...